Abiomed's Impella 2.5 enters new US trial
This article was originally published in Clinica
Executive Summary
A new clinical trial of Abiomed's Impella 2.5 circulatory support system is set to begin in the US following conditional FDA approval of the study protocol. The Impella device, already approved in Canada and CE marked in the EU, is inserted into the left ventricle in a minimally-invasive procedure, and helps pump blood in heart failure patients.